Trivalent cold recombinant influenza live vaccine in institutionalized children with bronchial asthma and patients with psychomotor retardation

• Published in: The Pediatric infectious disease journal Vol. 12; no. 7; p. 600
• Main Authors: Tanaka, Y, Ueda, K, Miyazaki, C, Nakayama, M, Kusuhara, K, Okada, K, Tokugawa, K, Shibata, R, Nishima, S, Yamane, N
• Format: Journal Article
• Language: English
• Published: United States 01.07.1993
• Subjects: Adolescent; Adult; Antibodies, Viral - biosynthesis; Asthma - immunology; Child; Child, Preschool; Cross Infection - prevention & control; Humans; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza, Human - prevention & control; Institutionalization; Orthomyxoviridae - immunology; Psychomotor Disorders - immunology; Vaccination; Virus Shedding
• ISSN: 0891-3668
• DOI: 10.1097/00006454-199307000-00011

Twenty asthmatic children and 48 patients with severe psychomotor retardation were inoculated intranasally with trivalent cold-adapted recombinant (CR) influenza vaccine containing CR-125 (H1N1), CR-159 (H3N2) and CRB-117 (B). The vaccinees were mostly seropositive. Severe adverse reactions or asthmatic attacks were not observed, but 7 (15%) of 48 vaccinees with severe psychomotor retardation developed mild to moderate fever. Significant antibody responses in hemagglutination-inhibition tests were demonstrated in 33 (49%) vaccinees to CR-125, 20 (29%) to CR-159 and 8 (12%) to CRB-117. Two nosocomial outbreaks of influenza were observed in the subsequent winter. During an outbreak with H3N2 in one ward of severe psychomotor retardation patients, 2 (11%) of 18 vaccinees became infected compared with 10 (48%) of 21 placebo controls in the same ward (P < 0.05). In the other outbreak, with influenza B virus, 2 (14%) of 14 vaccinees and 13 (52%) of 25 controls in the ward for asthmatic children were infected (P < 0.05). The results indicate that trivalent CR vaccine is safe and effective against nosocomial outbreaks of influenza.